ALTG 16/011 TROG 16.03 CORE: Conventional care Or Radioablation for Extracranial metastases – F Foroudi/ D Pryor

TROG 16.03 CORE is a phase II, international, non-blinded, randomised controlled trial in patients with breast, prostate or non-small cell lung cancer (NSCLC) primary cancer to evaluate if the addition of stereotactic body radiotherapy (SBRT) to standard therapy improves progression-free survival outcomes in patients with extra-cranial metastases that have spread from either their lung, breast and/or prostate cancer. The Institute of Cancer Research (ICR), UK have developed this study, with Trans Tasman Radiation Oncology Group (TROG) conducting the study in Australia.

The study is open in the UK and has recruited 36 participants (target accrual is 206). The first Australian centre is expected to be activated Q2 2017, with recruitment of TROG’s 50 participants to start in July. 8 sites have received HREC approval (13/12/2016); Princess Alexandra Hospital, Royal Brisbane and Women’s Hospital, Austin Health, Peter MacCallum Cancer Centre, Calvary Mater Newcastle, Westmead Hospital, Liverpool Hospital, & Royal Adelaide Hospital.

Study contacts

Trial Chairs: A/Prof David Pryor (PAH) david.pryor@health.qld.gov.au and A/Prof Farshad Foroudi (ONJWC) Farshad.FOROUDI@austin.org.au
Trial Co-ordinator: Courtney Hill, TROG Cancer Research     CORE@trog.com.au

Upcoming Events
  1. 4th ALTG Preceptorship in Lung Cancer, Melbourne, VIC

    August 17 - August 18
  2. Management Advisory Committee (MAC) Meeting

    August 31
  3. Scientific Advisory Committee (SAC) Meeting

    August 31
  4. 2018 ALTG Speaking Tour – Melbourne evening

    October 2 @ 6:00 pm - 9:00 pm
  5. 2018 ALTG Speaking Tour – Brisbane evening

    October 4 @ 6:00 pm - 9:00 pm